Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

CLCarmine LiberatoreTITakashi IkedaKGKaren Gogat-Marchant

Discussion

Loading...

Member takes

Overview

Observational analysis reports cytokine release syndrome in multiple myeloma patients treated with daratumumab, suggesting that tumor burden does not affect severity.

Key Points

  • Cytokine release syndrome occurred in 57.3% of patients, indicating a significant prevalence across treatment.
  • Most incidents of cytokine release syndrome were low grade, with generally mild toxicities observed.
  • The combined therapies included daratumumab, elranatamab, and lenalidomide, assessing their safety profiles.
  • Findings suggest that prior tumor debulking may not be necessary before daratumumab therapy in multiple myeloma patients.

Cite This Study

Liberatore et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df57https://doi.org/10.1182/blood-2025-2283
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A clinical overview of infection in patients receiving elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) for newly diagnosed multiple myeloma in the MagnetisMM-6 trial2025
  2. 2Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trial2025 · 8 citations
  3. 3Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study2025
  4. 4Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens2025
  5. 5Prolonged elranatamab treatment interruption in patients with relapsed or refractory multiple myeloma (RRMM) is feasible: A retrospective analysis from MagnetisMM-32025 · 3 citations